Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Iron sucrose

Iron sucrose: 1 brand, 3 generics; first approved Nov 06, 2000; generic available.

Generic available2 exclusivity periodsHas discontinued products
Generic status & protection

Generic available: 3 ANDA applications approved.

Latest exclusivity ends
Brands (NDA)
1
Generics (ANDA)
3
Listed patents
0
Presentations
14

Brand (NDA) products

Originator applications
Ask AI
  • NDA 02113520055 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 100MG IRON/5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSDiscontinued-
    EQ 200MG IRON/10ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSDiscontinued-

Generic (ANDA) products (3)

Abbreviated applications
Ask AI
  • IRON SUCROSE
    ANDA 20897720253 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 100MG IRON/5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 200MG IRON/10ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
  • IRON SUCROSE
    ANDA 21255920253 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 100MG IRON/5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 200MG IRON/10ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
  • IRON SUCROSE
    ANDA 21234020253 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 100MG IRON/5ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB
    EQ 200MG IRON/10ML (EQ 20MG IRON/ML)INJECTABLEINTRAVENOUSRxAB

Patent & exclusivity timeline

Protection horizon
Ask AI
20262027TodayExclusivity CGT: 2026-02-07Exclusivity CGTExclusivity CGT: 2026-02-08Exclusivity CGT
Patent expiryExclusivity endToday

Marketing exclusivity

Hatch-Waxman
Ask AI
  • CGTFDA marketing exclusivity

    9 mo ago

  • CGTFDA marketing exclusivity

    9 mo ago

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
Ask AI
First approval
26 yr 4 mo ago
Most recent approval
1 yr 3 mo ago

Approvals span 2000–2025 across 4 FDA applications.

Brand (NDA) 125%
Generic (ANDA) 375%

Iron sucrose: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Assyro Intelligence

Ask anything about Iron sucrose

Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.

  • PubMed
  • ClinicalTrials.gov
  • FDA
  • Health Canada
  • EMA
  • ICH

Evaluating for a team? Book a demo